ArticleBMC public health2025
From west to east: dissecting the global shift in inflammatory bowel disease burden and projecting future scenarios.
Article in BMC public health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed.
- Safety and Pharmacokinetics of Olamkicept Doses up to 2400 mg in Healthy Japanese Men: Phase I, Randomized, Placebo-Controlled, and Double-Blind Trial.Clinical and translational science · 2026Trial
- Chronotherapy in Inflammatory Bowel Disease: Biological Rationale, Human Evidence, and a Clinical Implementation Framework.Digestive diseases and sciences · 2026Review
- Perfluorooctanoic acid exposure disrupts gut microbiota and aggravates experimental colitis.Environmental pollution (Barking, Essex : 1987) · 2026Article
- Probiotics in Autoimmune Disease: Strain-specific Mechanisms and Therapeutic Perspectives.Clinical reviews in allergy & immunology · 2026Review
- Review
- Inflammatory bowel disease burden in China and the United States from 1990-2023 and prediction to 2050.Internal and emergency medicine · 2026Article
- Watercress Extract Reduces Experimental Colitis by Modulating Inflammation and Regulating the Gut Microbiota.Nutrients · 2026Article
- Challenges in Diagnosis and Management of Crohn's Disease in Bangladesh With Long Term Follow-Up.Clinical case reports · 2026Article
- Epidemiology and clinical profile of inflammatory bowel disease in Kuwait: a nationwide tertiary care (SEEF-IBD) study.BMC gastroenterology · 2026Article
- Characteristics of the Tongue Coating Microbiome and Its Subtype Differences in Patients with Inflammatory Bowel Disease.Microorganisms · 2026Article
- [1,3-dicaffeoylquinic acid mitigates dextran sulfate sodium-induced colitis in mice by alleviating oxidative stressNan fang yi ke da xue xue bao = Journal of Southern Medical University · 2026Article
- Current approaches to disease severity and therapy effectiveness assessment in patients with inflammatory bowel disease.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- Preferences, Expectations and Management Satisfaction in IBD Patients: A Cross-Sectional Questionnaire-Based Study.Journal of clinical medicine · 2026Article
- Understanding Frailty in IBD: Implications for Clinical Outcomes and Multidisciplinary Care.Journal of clinical medicine · 2026Review
- Characteristics of gut microbiota and metabolites in patients with ulcerative colitis with fatigue.World journal of gastroenterology · 2026Article
- Current and emerging approaches to manage chronic inflammatory gut disorders.Frontiers in cellular and infection microbiology · 2026Review
- AI-Guided Multi-Omic Microbiome Modulation Improves Clinical and Inflammatory Outcomes in Refractory IBD: A Real-World Study.International journal of molecular sciences · 2025Article
- Divergent trajectories of inflammatory bowel disease in East, South, South-East and Central Asia: A comprehensive GBD 2021 analysis.Journal of translational autoimmunity · 2025Article
- The Molecular Landscape of Inflammation in Inflammatory Bowel Disease (IBD): Targets for Precision Medicine.Biomedicines · 2025Review
- Engineered probiotics: a new era in treating inflammatory bowel disease.Journal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
backgroundThe epidemiology of inflammatory bowel disease (IBD) has changed dramatically worldwide. This survey analyzed patterns and trends in the burden of IBD to aid future decision making.
methodsThe incidence, prevalence, mortality, and disability-adjusted life year data for IBD were derived from the GBD (Global Burden of Disease) study.
resultsIn 2021, there were 3,830,119 cases of IBD worldwide, including 375,140 new cases, 42,423 IBD-related deaths, and 1,510,784-year healthy life loss due to IBD. The burden of IBD is usually concentrated in regions and countries with high sociodemographic indices(SDI). In 2021, the number of cases (2,000,478) and deaths (22,968) in women were higher than those in men, but the number of new cases in men was higher (188,005 cases). At the global, regional, and national levels, the number of IBD-related illnesses and deaths is still slowly increasing, but the age-standardized rate(ASR) is on a downward trend. The decomposition analysis showed that the change in the burden of IBD was mainly due to the growth of the global population. Frontier analysis showed that age-standardized incidence rate(ASIR) were positively correlated with sociodemographic indexes. As SDI declines, IBD ASIR’s effective difference (EF) for a particular SDI is smaller.
conclusionAs a major global public health issue, there are significant regional differences in the burden of IBD. There data are crucial for healthcare professionals, policymakers, and researchers to refine and enhance management strategies, aiming to further mitigate IBD ‘s global impact.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.